{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:37:26Z","timestamp":1791549446009,"version":"4.3.4"},"reference-count":50,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100006250","name":"Southwest University","doi-asserted-by":"publisher","award":["SWU110056"],"award-info":[{"award-number":["SWU110056"]}],"id":[{"id":"10.13039\/501100006250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006250","name":"Southwest University","doi-asserted-by":"publisher","award":["SWU110057"],"award-info":[{"award-number":["SWU110057"]}],"id":[{"id":"10.13039\/501100006250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2020,7,29]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>This study aimed to reduce the amount of sulfobutylether-\u03b2-cyclodextrin (SBECD) used in\nthe marketed voriconazole injections to meet the clinical needs of patients with moderate-to-severe renal impairment\n(creatinine clearance rate &lt;50 mL\/min).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study found that the surfactant Kolliphor\u00ae HS 15 (HS 15) and SBECD had significant synergistic\neffects on solubilizing voriconazole, and a novel voriconazole complex delivery system (VRC-CD\/HS 15) was\nestablished.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The complex system was characterized, and its antifungal activity was studied by dynamic light scattering,\ndialysis bag method, disk diffusion, and broth microdilution.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Result:<\/jats:title>\n<jats:p>Compared with the control, its encapsulation efficiency (90.07\u00b10.48%), drug loading (7.37\u00b10.25%) and zeta\npotential (-4.36\u00b11.37 mV) were increased by 1.54%, 41.19%, and 296.36%, respectively; its average particle size\n(13.92\u00b10.00 nm) was reduced by 15.69%, so the complex system had better stability. Simultaneously, its drug release\nbehavior was similar to that of the control, and it was a first-order kinetic model. Antifungal studies indicated that the\ncomplex system had noticeable antifungal effects. With the increase of drug concentration, the inhibition zone\nincreased. The minimum inhibitory concentrations of the complex system against Cryptococcus neoformans,\nAspergillus niger and Candida albicans were 0.0313 \u03bcg\/mL, 1 \u03bcg\/mL and 128 \u03bcg\/mL, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>It showed a significant inhibitory effect on C. neoformans and had a visible therapeutic effect on\nKunming mice infected with C. neoformans. Consequently, VRC-CD\/HS 15 had better physicochemical properties\nand still had an apparent antifungal effect, and was promising as a potential alternative drug for clinical application.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200221666200520085915","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T16:51:32Z","timestamp":1589993492000},"page":"379-389","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Kolliphor\u00ae HS 15-cyclodextrin Complex for the Delivery of Voriconazole: Preparation, Characterization, and Antifungal Activity"],"prefix":"10.2174","volume":"21","author":[{"given":"Yiqi","family":"Li","sequence":"first","affiliation":[{"name":"College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhu","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchun","family":"Pan","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.tim.2017.02.013","volume":"25(6)","author":"Armstrong-James,D.","year":"2017","unstructured":"Armstrong-James,D.; Bicanic,T.; Brown, G.D.; Hoving, J.C.; Meintjes,G.; Nielsen, K. Working Group from the EMBO Workshop on AIDS-Related Mycoses. AIDS-related mycoses: current progress in the field and future priorities. Trends Microbiol. 2017,25(6),428-430. http:\/\/dx.doi.org\/10.1016\/j.tim.2017.02.013 PMID: 28454846","journal-title":".Trends Microbiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1111\/ajt.14940","volume":"18(9)","author":"Pilmis,B.","year":"2018","unstructured":"Pilmis,B.; Garcia-Hermoso,D.; Alanio,A.; Catherinot,E.; Scemla,A.; Jullien,V.; Bretagne,S.; Lortholary, O. Failure of voriconazole therapy due to acquired azole resistance in Aspergillus fumigatus in a kidney transplant recipient with chronic necrotizing aspergillosis. Am, J. Transplant. 2018,18(9),2352-2355. http:\/\/dx.doi.org\/10.1111\/ajt.14940 PMID: 29790292","journal-title":"Am, J.Transplant"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pupt.2014.06.002","volume":"32","author":"Bassetti,M.","year":"2015","unstructured":"Bassetti,M.; Pecori,D.; Della Siega,P.; Corcione,S.; De Rosa, F.G. Current and future therapies for invasive aspergillosis. Pulm. Pharmacol. Ther. 2015,32,155-165. http:\/\/dx.doi.org\/10.1016\/j.pupt.2014.06.002 PMID: 24994691","journal-title":"Pulm.Pharmacol.Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(18) 30030-9","volume":"17(4)","author":"Schwartz,S.","year":"2018","unstructured":"Schwartz,S.; Kontoyiannis, D.P.; Harrison,T.; Ruhnke, M. Advances in the diagnosis and treatment of fungal infections of the CNS. Lancet Neurol. 2018,17(4),362-372. http:\/\/dx.doi.org\/10.1016\/S1474-4422(18) 30030-9 PMID: 29477506","journal-title":"Lancet Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejps.2009.02.021","volume":"37(3-4)","author":"Jung, S.H.","year":"2009","unstructured":"Jung, S.H.; Lim, D.H.; Jung, S.H.; Lee, J.E.; Jeong, K-S.; Seong,H.; Shin, B.C. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur, J. Pharm. Sci. 2009,37(3-4),313-320. http:\/\/dx.doi.org\/10.1016\/j.ejps.2009.02.021 PMID: 19491021","journal-title":"Eur, J.Pharm.Sci"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01291-18","author":"Bhattacharya,S.","unstructured":"Bhattacharya,S.; Esquivel, B.D.; White, T.C. Overexpression or deletion of ergosterol biosynthesis genes alters doubling time, response to stress agents, and drug susceptibility in Saccharomyces cerevisiae. MBio. 2018,9(4) e01291-18 http:\/\/dx.doi.org\/10.1128\/mBio.01291-18 PMID: 30042199","journal-title":"MBio"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/INF.0000000000001913","volume":"37(9)","author":"Autmizguine,J.","year":"2018","unstructured":"Autmizguine,J.; Tan,S.; Cohen-Wolkowiez,M.; Cotten, C.M.; Wiederhold,N.; Goldberg, R.N.; Adams-Chapman,I.; Stoll, B.J.; Smith, P.B.; Benjamin, D.K. Jr NICHD Neonatal Research Network. Antifungal susceptibility and clinical outcome in neonatal candidiasis. Pediatr. Infect. Dis, J. 2018,37(9),923-929. http:\/\/dx.doi.org\/10.1097\/INF.0000000000001913 PMID: 29369937","journal-title":"Pediatr.Infect.Dis, J"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/myc.12747","volume":"61(5)","author":"Bongomin,F.","year":"2018","unstructured":"Bongomin,F.; Oladele, R.O.; Gago,S.; Moore, C.B.; Richardson, M.D. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses. 2018,61(5),290-297. http:\/\/dx.doi.org\/10.1111\/myc.12747 PMID: 29377368","journal-title":"Mycoses"},{"key":"ref=9","author":"Park, S.Y.","unstructured":"Park, S.Y.; Yoon, J.A.; Kim, S.H. Voriconazole-refractory invasive aspergillosis. Korean J. Intern. Med. (Korean. Assoc. Intern. Med.),2017,32(5),805-812. http:\/\/dx.doi.org\/10.3904\/kjim.2017.109 PMID: 28835093","journal-title":"Korean J.Intern.Med.(Korean.Assoc.Intern.Med.)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1128\/AAC.00850-13","volume":"57(10)","author":"Hazirolan,G.","year":"2013","unstructured":"Hazirolan,G.; Canton,E.; Sahin,S.; Arikan-Akdagli, S. Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii. Antimicrob. Agents Chemother. 2013,57(10),4841-4847. http:\/\/dx.doi.org\/10.1128\/AAC.00850-13 PMID: 23877683","journal-title":"Antimicrob.Agents Chemother"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0149-2918(03) 80126-1","volume":"25(5)","author":"Jeu,L.","year":"2003","unstructured":"Jeu,L.; Piacenti, F.J.; Lyakhovetskiy, A.G.; Fung, H.B. Voriconazole. Clin. Ther. 2003,25(5),1321-1381. http:\/\/dx.doi.org\/10.1016\/S0149-2918(03) 80126-1 PMID: 12867215","journal-title":"Clin.Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.mycmed.2017.11.008","volume":"28(1)","author":"Gon\u00e7alves Silva,E.","year":"2018","unstructured":"Gon\u00e7alves Silva,E.; Marilia de Souza Silva,S.; Rodrigues Paula,C.; da Silva Ruiz,L.; Latercia Tranches Dias, A. Modulatory effect of voriconazole on the production of proinflammatory cytokines in experimental cryptococcosis in mice with severe combined immunodeficiency, J. Mycol. Med. 2018,28(1),106-111. http:\/\/dx.doi.org\/10.1016\/j.mycmed.2017.11.008 PMID: 29273275","journal-title":"Mycol.Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2217\/17460913.1.4.365","volume":"1(4)","author":"Maschmeyer,G.","year":"2006","unstructured":"Maschmeyer,G.; Haas, A. Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections. Future Microbiol. 2006,1(4),365-385. http:\/\/dx.doi.org\/10.2217\/17460913.1.4.365 PMID: 17661629","journal-title":"Future Microbiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/myc.12727","volume":"61(3)","author":"Hoenigl,M.","year":"2018","unstructured":"Hoenigl,M.; Prattes,J.; Neumeister,P.; W\u00f6lfler,A.; Krause, R. Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study. Mycoses. 2018,61(3),201-205. http:\/\/dx.doi.org\/10.1111\/myc.12727 PMID: 29112326","journal-title":"Mycoses"},{"key":"ref=15","first-page":"1240","volume":"42(10)","author":"Angulo. .","year":"2019","unstructured":"Angulo.; N. Description of adverse reactions found in patients who received voriconazole in the university IPS from the period of May 2013 to March 2015. Drug Saf. 2019,42(10),1240-1241","journal-title":"Drug Saf"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1472-6904-6-6","volume":"6","author":"von Mach, M.A.","year":"2006","unstructured":"von Mach, M.A.; Burhenne,J.; Weilemann, L.S. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin. Pharmacol. 2006,6,6. http:\/\/dx.doi.org\/10.1186\/1472-6904-6-6 PMID: 16981986","journal-title":"BMC Clin.Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1185\/030079903125001884","volume":"19(4)","author":"Ullmann,A.J","year":"2003","unstructured":"Ullmann.; A.J. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opin. 2003,19(4),263-271. http:\/\/dx.doi.org\/10.1185\/030079903125001884 PMID: 12841918","journal-title":"Curr.Med.Res.Opin"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jcph.1077","volume":"58(6)","author":"Hoover, R.K.","year":"2018","unstructured":"Hoover, R.K.; Alcorn, H. Jr; Lawrence,L.; Paulson, S.K.; Quintas,M.; Luke, D.R.; Cammarata, S.K. Clinical pharmacokinetics of sulfobutylether-\u00df-cyclodextrin in patients with varying degrees of renal impairment, J. Clin. Pharmacol. 2018,58(6),814-822. http:\/\/dx.doi.org\/10.1002\/jcph.1077 PMID: 29578585","journal-title":"J.Clin.Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1128\/AAC.01540-09","volume":"54(6)","author":"Hafner,V.","year":"2010","unstructured":"Hafner,V.; Czock,D.; Burhenne,J.; Riedel, K-D.; Bommer,J.; Mikus,G.; Machleidt,C.; Weinreich,T.; Haefeli, W.E. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob. Agents Chemother. 2010,54(6),2596-2602. http:\/\/dx.doi.org\/10.1128\/AAC.01540-09 PMID: 20368400","journal-title":"Antimicrob.Agents Chemother"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1002\/jps.22109","volume":"99(8)","author":"Luke, D.R.","year":"2010","unstructured":"Luke, D.R.; Tomaszewski,K.; Damle,B.; Schlamm, H.T. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD) . J. Pharm. Sci. 2010,99(8),3291-3301. http:\/\/dx.doi.org\/10.1002\/jps.22109 PMID: 20213839","journal-title":"J.Pharm.Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jconrel.2012.06.014","volume":"162(1)","author":"Illum,L.","year":"2012","unstructured":"Illum,L.; Jordan,F.; Lewis, A.L. CriticalSorb: a novel efficient nasal delivery system for human growth hormone based on Solutol HS15. J. Control. Release. 2012,162(1),194-200. http:\/\/dx.doi.org\/10.1016\/j.jconrel.2012.06.014 PMID: 22709592","journal-title":"J.Control.Release"},{"key":"ref=22","first-page":"1339","volume":"33","author":"Lan,L.","year":"2017","unstructured":"Lan,L.; Zhou,Q.; Yang, X. Preparation of vinorelbine tartrate thermosensitive liposomes and measurement of its encapsulation efficiency. Acta Med. Mediter. 2017,33,1339-1343","journal-title":"Acta Med..Mediter"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejps.2005.01.020","volume":"25(1)","author":"Ruozi,B.","year":"2005","unstructured":"Ruozi,B.; Tosi,G.; Forni,F.; Fresta,M.; Vandelli, M.A. Atomic force microscopy and photon correlation spectroscopy: two techniques for rapid characterization of liposomes. Eur, J. Pharm. Sci. 2005,25(1),81-89. http:\/\/dx.doi.org\/10.1016\/j.ejps.2005.01.020 PMID: 15854804","journal-title":"Eur, J.Pharm.Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1039\/c2nr31517c","volume":"4(19)","author":"Gong,C.","year":"2012","unstructured":"Gong,C.; Xie,Y.; Wu,Q.; Wang,Y.; Deng,S.; Xiong,D.; Liu,L.; Xiang,M.; Qian,Z.; Wei, Y. Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. Nanoscale. 2012,4(19),6004-6017. http:\/\/dx.doi.org\/10.1039\/c2nr31517c PMID: 22910790","journal-title":"Nanoscale"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1208\/s12249-015-0399-5","volume":"17(3)","author":"Liu,L.","year":"2016","unstructured":"Liu,L.; Mao,K.; Wang,W.; Pan,H.; Wang,F.; Yang,M.; Liu, H. Kolliphor\u00ae HS 15 micelles for the delivery of coenzyme q10: preparation, characterization, and stability. AAPS PharmSciTech. 2016,17(3),757-766. http:\/\/dx.doi.org\/10.1208\/s12249-015-0399-5 PMID: 26340950","journal-title":"AAPS PharmSciTech"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11051-014-2838-8","volume":"17(1)","author":"Unal,H.","year":"2015","unstructured":"Unal,H.; d\u2019Angelo,I.; Pagano,E.; Borrelli,F.; Izzo,A.; Ungaro, F. Core-shell hybrid nanocapsules for oral delivery of camptothecin: formulation development, in vitro and in vivo evaluation, J. Nanopart. Res. 2015,17(1),1-13. http:\/\/dx.doi.org\/10.1007\/s11051-014-2838-8","journal-title":"Nanopart.Res"},{"key":"ref=27","author":"Khafri, H.Z.","unstructured":"Khafri, H.Z.; Ghaedi,M.; Asfaram,A.; Javadian,H.; Safarpoor, M. Synthesis of CuS and ZnO\/Zn(OH) (2)  nanoparticles and their evaluation for in vitro antibacterial and antifungal activities. Appl. Organomet. Chem. 2018,32(7)","journal-title":"Appl.Organomet..Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ica.2013.01.031","volume":"400","author":"Ozdemir, U.O.","year":"2013","unstructured":"Ozdemir, U.O.; Akkaya,N.; Ozbek, N. New nickel(II),palladium(II),platinum(II)  complexes with aromatic methanesulfonylhydrazone based ligands. Synthesis, spectroscopic characterization and in vitro antibacterial evaluation. Inorg. Chim. Acta. 2013,400,13-19. http:\/\/dx.doi.org\/10.1016\/j.ica.2013.01.031","journal-title":"Inorg.Chim.Acta"},{"key":"ref=29","unstructured":"Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3., 3rd ed.; CLSI, Wayne PA, USA. 2008"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.micpath.2018.08.023","volume":"124","author":"Rishi,P.","year":"2018","unstructured":"Rishi,P.; Vij,S.; Maurya, I.K.; Kaur, U.J.; Bharati,S.; Tewari, R. Peptides as adjuvants for ampicillin and oxacillin against methicillin-resistant Staphylococcus aureus (MRSA) . Microb. Pathog. 2018,124,11-20. http:\/\/dx.doi.org\/10.1016\/j.micpath.2018.08.023 PMID: 30118800","journal-title":"Microb.Pathog"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1128\/AAC.44.7.1917-1920.2000","volume":"44(7)","author":"Klepser, M.E.","year":"2000","unstructured":"Klepser, M.E.; Malone,D.; Lewis, R.E.; Ernst, E.J.; Pfaller, M.A. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob. Agents Chemother. 2000,44(7),1917-1920. http:\/\/dx.doi.org\/10.1128\/AAC.44.7.1917-1920.2000 PMID: 10858354","journal-title":"Antimicrob.Agents Chemother"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/626745","author":"Sabiiti,W.","unstructured":"Sabiiti,W.; May, R.C.; Pursall, E.R. Experimental models of cryptococcosis. Int, J. Microbiol. 2012,2012626745 http:\/\/dx.doi.org\/10.1155\/2012\/626745 PMID: 22007224","journal-title":"Int, J.Microbiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/jac\/dkx020","volume":"72(6)","author":"Nishikawa,H.","year":"2017","unstructured":"Nishikawa,H.; Fukuda,Y.; Mitsuyama,J.; Tashiro,M.; Tanaka,A.; Takazono,T.; Saijo,T.; Yamamoto,K.; Nakamura,S.; Imamura,Y.; Miyazaki,T.; Kakeya,H.; Yamamoto,Y.; Yanagihara,K.; Mukae,H.; Kohno,S.; Izumikawa, K. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen, J. Antimicrob. Chemother. 2017,72(6),1709-1713. http:\/\/dx.doi.org\/10.1093\/jac\/dkx020 PMID: 28201509","journal-title":"Antimicrob.Chemother"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.colsurfa.2014.12.024","volume":"480","author":"Fajalia, AI.","year":"2015","unstructured":"Fajalia, AI.; Tsianou, M Self-assembly control via molecular recognition: effect of cyclodextrins on surfactant micelle structure and interactions determined by SANS. Colloid. Surf. Physicochem. Engin. Aspect. 2015,480,91-104","journal-title":"Surf.Physicochem..Engin.Aspect"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","volume":"12(3)","author":"Zhang,Y.","year":"2010","unstructured":"Zhang,Y.; Huo,M.; Zhou,J.; Zou,A.; Li,W.; Yao,C.; Xie, S. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010,12(3),263-271. http:\/\/dx.doi.org\/10.1208\/s12248-010-9185-1 PMID: 20373062","journal-title":"AAPS J"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.micpath.2017.12.068","volume":"115","author":"Parveen,S.","year":"2018","unstructured":"Parveen,S.; Wani, A.H.; Shah, M.A.; Devi, H.S.; Bhat, M.Y.; Koka, J.A. Preparation, characterization and antifungal activity of iron oxide nanoparticles. Microb. Pathog. 2018,115,287-292. http:\/\/dx.doi.org\/10.1016\/j.micpath.2017.12.068 PMID: 29306005","journal-title":"Microb.Pathog"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/sim.7689","volume":"37(20)","author":"Moellenhoff,K.","year":"2018","unstructured":"Moellenhoff,K.; Dette,H.; Kotzagiorgis,E.; Volgushev,S.; Collignon, O. Regulatory assessment of drug dissolution profiles comparability via maximum deviation. Stat. Med. 2018,37(20),2968-2981. http:\/\/dx.doi.org\/10.1002\/sim.7689 PMID: 29862526","journal-title":"Stat.Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.colsurfb.2013.02.043","volume":"108","author":"Ige, P.P.","year":"2013","unstructured":"Ige, P.P.; Baria, R.K.; Gattani, S.G. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf. B Biointerfaces. 2013,108,366-373. http:\/\/dx.doi.org\/10.1016\/j.colsurfb.2013.02.043 PMID: 23602990","journal-title":"Colloids Surf.B Biointerfaces"},{"key":"ref=39","first-page":"311","volume":"67(4)","author":"Tan, Q.Y.","year":"2012","unstructured":"Tan, Q.Y.; Xu, M.L.; Wu, J.Y.; Yin, H.F.; Zhang, J.Q. Preparation and characterization of poly(lactic acid)  nanoparticles for sustained release of pyridostigmine bromide. Pharmazie. 2012,67(4),311-318. PMID: 22570937","journal-title":"Pharmazie"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0168-3659(01) 00248-6","volume":"73(2-3)","author":"Huang,X.","year":"2001","unstructured":"Huang,X.; Brazel, C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems, J. Control. Release. 2001,73(2-3),121-136. http:\/\/dx.doi.org\/10.1016\/S0168-3659(01) 00248-6 PMID: 11516493","journal-title":"Control.Release"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11706-012-0176-2","volume":"6(3)","author":"Zhou, H.Y.","year":"2012","unstructured":"Zhou, H.Y.; Jiang, L.J.; Zhang, Y.P.; Li, J.B. Beta-cyclodextrin inclusion complex: preparation, characterization, and its aspirin release in vitro. Front. Mater. Sci. 2012,6(3),259-267. http:\/\/dx.doi.org\/10.1007\/s11706-012-0176-2","journal-title":"Front.Mater.Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ijbiomac.2018.06.125","volume":"118(Pt A)","author":"Matshetshe, K.I.","year":"2018","unstructured":"Matshetshe, K.I.; Parani,S.; Manki, S.M.; Oluwafemi, O.S. Preparation, characterization and in vitro release study of \u00df-cyclodextrin\/chitosan nanoparticles loaded Cinnamomum zeylanicum essential oil. Int, J. Biol. Macromol. 2018,118(Pt A),676-682. http:\/\/dx.doi.org\/10.1016\/j.ijbiomac.2018.06.125 PMID: 29959997","journal-title":"Int, J.Biol.Macromol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1128\/AAC.00163-06","volume":"50(6)","author":"Sabatelli,F.","year":"2006","unstructured":"Sabatelli,F.; Patel,R.; Mann, P.A.; Mendrick, C.A.; Norris, C.C.; Hare,R.; Loebenberg,D.; Black, T.A.; McNicholas, P.M. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 2006,50(6),2009-2015. http:\/\/dx.doi.org\/10.1128\/AAC.00163-06 PMID: 16723559","journal-title":"Antimicrob.Agents Chemother"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jac\/dkm123","volume":"60(1)","author":"Serena,C.","year":"2007","unstructured":"Serena,C.; Pastor, F.J.; Marin\u00e9, M.; Rodr\u00edguez, M.M.; Guarro, J. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection, J. Antimicrob. Chemother. 2007,60(1),162-165. http:\/\/dx.doi.org\/10.1093\/jac\/dkm123 PMID: 17483143","journal-title":"Antimicrob.Chemother"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s100960050313","volume":"18(6)","author":"Cuenca-Estrella,M.","year":"1999","unstructured":"Cuenca-Estrella,M.; D\u00edaz-Guerra, T.M.; Mellado,E.; Monz\u00f3n,A.; Rodr\u00edguez-Tudela, J.L. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur, J. Clin. Microbiol. Infect. Dis. 1999,18(6),432-435. http:\/\/dx.doi.org\/10.1007\/s100960050313 PMID: 10442422","journal-title":"Eur, J.Clin.Microbiol.Infect.Dis"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/525258","volume":"46(3)","author":"Walsh, T.J.","year":"2008","unstructured":"Walsh, T.J.; Anaissie, E.J.; Denning, D.W.; Herbrecht,R.; Kontoyiannis, D.P.; Marr, K.A.; Morrison, V.A.; Segal, B.H.; Steinbach, W.J.; Stevens, D.A.; van Burik, J.A.; Wingard, J.R.; Patterson, T.F. Infectious diseases society of america. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008,46(3),327-360. http:\/\/dx.doi.org\/10.1086\/525258 PMID: 18177225","journal-title":"Clin.Infect.Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.02.006","volume":"34(3)","author":"Li,Y.","year":"2009","unstructured":"Li,Y.; Nguyen, M.H.; Schmidt,S.; Zhong,L.; Derendorf,H.; Clancy, C.J. Pharmacokinetic\/pharmacodynamic modelling and in vitro simulation of dynamic voriconazole-Candida interactions. Int, J. Antimicrob. Agents. 2009,34(3),240-245. http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2009.02.006 PMID: 19339162","journal-title":"Int, J.Antimicrob.Agents"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijantimicag.2006.01.003","volume":"27(4)","author":"Lev\u00eaque,D.","year":"2006","unstructured":"Lev\u00eaque,D.; Nivoix,Y.; Jehl,F.; Herbrecht, R. Clinical pharmacokinetics of voriconazole. Int, J. Antimicrob. Agents. 2006,27(4),274-284. http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2006.01.003 PMID: 16563707","journal-title":"Int, J.Antimicrob.Agents"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11046-011-9499-2","volume":"173(5-6)","author":"Silva, E.G.","year":"2012","unstructured":"Silva, E.G.; Paula, C.R.; de Assis Baroni,F.; Gambale, W. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A)  in mice with severe combined immunodeficiency (SCID) . Mycopathologia. 2012,173(5-6),445-449. http:\/\/dx.doi.org\/10.1007\/s11046-011-9499-2 PMID: 22071662","journal-title":"Mycopathologia"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00405-014-3269-y","volume":"272(8)","author":"Wang,T.","year":"2015","unstructured":"Wang,T.; Su,J.; Feng, Y. The effectiveness topical amphotericin B in the management of chronic rhinosinusitis: a meta-analysis. Eur. Arch. Otorhinolaryngol. 2015,272(8),1923-1929. http:\/\/dx.doi.org\/10.1007\/s00405-014-3269-y PMID: 25217082","journal-title":"Eur.Arch.Otorhinolaryngol"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/182137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T11:55:39Z","timestamp":1603454139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/182137\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,7,29]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221666200520085915","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}